Baird Financial Group
LUMO

Baird Financial Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Baird Financial Group’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,815
Closed -$168K – 1254
2016
Q4 		$168K Buy
+1,815
New +$205K ﹤0.01% 1149

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Baird Financial Group's LUMO Position: Q1 2017 in Review

Baird Financial Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2017, closing a stake of 1,815 shares — an estimated $168K sold.

Baird Financial Group first reported a position in LUMO in Q4 2016 and held it in 1 quarter. The position peaked at $168K in Q4 2016. 128 funds tracked by Wall St. Rank hold LUMO as of Q1 2017.

  • Baird Financial Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Baird Financial Group sold 1,815 Lumos Pharma, Inc. Common Stock shares in Q1 2017, an estimated $168K.
  • Baird Financial Group first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Baird Financial Group's Lumos Pharma, Inc. Common Stock position peaked at $168K in Q4 2016.
  • 128 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2017.

Based on Baird Financial Group's 13F filing for Q1 2017, filed 9 May 2017.